Category: Alzheimer’s

Biogen withdraws marketing authorisation application for aducanumab for Alzheimer’s disease

Posted on 28 April, 2022 - Alzheimer's Disease

Biogen has informed the European Medicines Agency (EMA) that it is withdrawing its application for marketing authorisation for aducanumab for the treatement of Alzheimer’s disease The EMA had previously found on 16 December 2021 that the benefits of aducanumab did not outweigh its risks and recommended refusing marketing authorisation. Biogen then requested a re-examination. Following…